CytomX Therapeutics, Inc.
Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor

Last updated:

Abstract:

The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Status:
Grant
Type:

Utility

Filling date:

19 Dec 2016

Issue date:

14 Jan 2020